Category News

PRESS RELEASE: Oxford, UK and South Korea, 3rd June 2019: KwangDong Pharmaceutical Co. Ltd and Oxford Cancer Biomarkers Ltd. agree a significant investment partnership

Oxford Cancer Biomarkers (OCB) has gained a significant investment from leading South Korean healthcare company KwangDong Pharmaceutical Co. Ltd. (KDP). This investment marks an exciting new commercial phase for the Oxford university spin-out as the company translates innovative cancer biomarker…

Announcing The Launch Of Our New Website

Blue orange creative office startup job vacancy twitter post

We are pleased to announce the launch of Oxford Cancer Biomarkers’ newly designed website www.oxfordbio.com. In redesigning our site, our goal is to provide a user-friendly browsing experience, in which to learn about our pioneering cancer biomarker technologies.  We will…

OCB Launches ToxNav in the UK Market

Ocb toxnav

Oxford Cancer Biomarkers launches ToxNav to improve morbidity and mortality rates in patients undergoing CRC chemotherapy Oxford, UK, 28 June 2018: Oxford Cancer Biomarkers Limited (www.oxfordbio.com) has announced the launch of ToxNav – a genomic test to identify cancer patients…

OCB present ToxNav on ESMO-GI 2018

Esmo 2018

ESMO World Congress on Gastrointestinal Cancer Barcelona, Spain 20-23 Jun 2018 At ESMO-GI on 22nd June 2018 OCB was pleased to display the poster showing the clinical utility of ToxNav in predicting the most serious capecitabine-related toxicities. The data also…